EUCTR2005-005672-33-GB进行中（未招募）1 期
A Randomized, Controlled, Open-Label, 48-Week Study of Continuing Successfully Suppressive Treatment in HIV-1 Infected Adults with First-Line Twice-Daily Zidovudine and Lamivudine-Based Regimens versus Proactively Replacing of Zidovudine and Lamivudine by Once-Daily Emtricitabine and Tenofovir Disoproxil Fumarate to Prevent Progression of or Reverse Peripheral Lipoatrophy. - PREPARE
IATEC B.V.0 个研究点目标入组 120 人开始时间: 2006年3月3日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •- HIV-1 infected patients.
- •- At least 18 years of age.
- •- Males or non-pregnant, non-lactating females.
- •- Treatment for over two years with a first-line regimen of zidovudine plus lamivudine (as either a fixed dose combination or dosed separately) plus either an NNRTI or a (boosted) PI. Patients may have previously used multiple drugs from both the NNRTI or the PI classes.
- •- Plasma HIV-1 RNA levels < 50 copies/mL for at least 6 months.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Prior treatment with an NRTI other than zidovudine or lamivudine.
- •- Use of a triple NRTI antiretroviral regimen or a regimen including unboosted saquinavir, fusion inhibitors or hydroxyurea
- •- Prior virological treatment failure, defined as having had to switch to antiretroviral therapy because of virologic failure in the opinion of the physician.
- •- HIV-2 co-infection.
- •- Renal impairment and/or use of nephrotoxic agents which in the opinion of the investigator are a contraindication for the use of tenofovir disoproxil fumarate.
- •- Clinically relevant laboratory abnormalities: anemia, trombocytopenia, leucopenia, elevated liver transaminases, elevated bilirubin, elevated amylase, elevated lipase.
- •- Use of co-medication, other than antiretroviral drugs, with a known pharmacological interaction with one or more of the study drugs
- •- Active alcohol or drug use, sufficient in the investigator’s opinion to prevent compliance with the dosing schedule and evaluations (methadone and buprenorphine use is allowed, although the dose of methadone might need to be adjusted).
- •- Anticipated non-compliance with the protocol.
- •- Presence of a newly (within 30 days prior to the time of enrolment) diagnosed HIV-related opportunistic infection or condition which may interfere with the ability to comply with the study.
- •- Chronic active viral hepatitis or other chronic liver disease, which in the opinion of the investigator is a contraindication for the use of any of the study drugs.
- •- Women who have the intention to become pregnant during the study period.
- •- Patients who have received within 4 weeks prior to entry, or who have an anticipated need for treatment with radiation therapy or cytotoxic chemotherapeutic agents during the protocol study period.
- •- Patients who have taken any investigational drug 30 days prior to the start of the study
- •- Patients with malabsorption syndrome or other gastrointestinal dysfunction which may interfere with drug absorption or prevent the patient from taking oral medication.
研究者
相似试验
进行中（未招募）
不适用
A Randomized, Controlled, Open-Label, 48-Week Study of Continuing Successfully Suppressive Treatment in HIV-1 Infected Adults with First-Line Twice-Daily Zidovudine and Lamivudine-Based Regimens versus Proactively Replacing of Zidovudine and Lamivudine by Once-Daily Emtricitabine and Tenofovir Disoproxil Fumarate to Prevent Progression of or Reverse Peripheral Lipoatrophy. - PREPAREHIV-1 infectionEUCTR2005-005672-33-FIIATEC B.V.120
进行中（未招募）
1 期
A Randomised, Controlled, Open-Label, 48-Week, Study To Asses Differences in Changes In Plasma Lipid Profile Between Patients On Saquinavir/Ritonavir Or Atazanavir/Ritonavir In Combination With Tenofovir Disoproxil Fumarate And Emtricitabine As A First-line Regimen. BASIC (Boosted Atazanavir or Saquinavir Induced Lipid Changes) - BASICEUCTR2006-000666-37-GBIATEC B.V.120
进行中（未招募）
不适用
A Randomised, Controlled, Open-Label, 48-Week, Study To Asses Differences in Changes In Plasma Lipid Profile Between Patients On Saquinavir/Ritonavir Or Atazanavir/Ritonavir In Combination With Tenofovir Disoproxil Fumarate And Emtricitabine As A First-line Regimen.BASIC (Boosted Atazanavir or Saquinavir Induced Lipid Changes) - BASICHIV-1 infectionEUCTR2006-000666-37-DEIATEC B.V.120
进行中（未招募）
1 期
Comparison of MyStar DoseCoach to routine titration in Adult Patients with Type 2 Diabetes Mellitus using ToujeoType 2 diabetes mellitusMedDRA version: 18.1 Level: PT Classification code 10067585 Term: Type 2 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2014-004533-13-GBSanofi-aventis recherche & développement151
进行中（未招募）
1 期
Comparison of MyStar DoseCoach to routine titration in Adult Patients with Type 2 Diabetes Mellitus using ToujeoType 2 diabetes mellitusMedDRA version: 18.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2014-004533-13-DESanofi-aventis recherche & développement151